Showing 2061-2070 of 2652 results for "".
- Aviceda Announces Topline Data From Part 1 of the Phase 2/3 SIGLEC Trial of GA Drug Candidate AVD-104https://modernod.com/news/aviceda-therapeutics-announces-topline-data-from-part-1-of-the-phase-23-siglec-clinical-trial-for-avd-104-demonstrating-positive-safety-and-early-clinical-efficacy-in-patients-with-geographic-atrophy/2482061/Aviceda Therapeutics announced positive topline data of part 1 of the phase 2/3 SIGLEC trial for AVD-104 in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD), showing positive safety and efficacy outcomes which were observed at 3 months after a single
- IntRIS Hosts ARCR Macular 2024 Meeting and Presents Interview With FDA’s Dr. Wiley Chambershttps://modernod.com/news/intris-hosts-arcr-macular-2024-meeting-and-presents-interview-with-fdas-dr-wiley-chambers/2482057/The International Retinal Imaging Society (IntRIS) hosted the Atlantic Coast Retina Club (ACRC) Macula 2024, led by K. Bailey Freund, MD. According IntRIS, the ACRC meeting format includes rapid-fire single-case presentations, engaging discussions, and conferences covering diverse retin
- Alkeus’ Gildeuretinol Studied to Halt Progression of Early-Stage Stargardt Diseasehttps://modernod.com/news/alkeus-gildeuretinol-studied-to-halt-progression-of-early-stage-stargardt-disease/2482055/Alkeus Pharmaceuticals announced positive interim data showing gildeuretinol halted Stargardt disease progression for up to 6 years in the ongoing TEASE-3 clinical trial. The first three teenage patients with early-stage Stargardt disease enrolled in the trial and treated with oral gild
- Aetna Rolls Back Prior Authorization for Cataract Surgeries for Medicare Advantage Beneficiaries in Georgiahttps://modernod.com/news/aetna-rolls-back-prior-authorization-for-cataract-surgeries-for-medicare-advantage-beneficiaries-in-georgia-1/2482030/After 2 years of advocacy from the ophthalmology community, Aetna confirmed in a letter to the American Academy of Ophthalmology that it will no longer require preapproval for cataract surgeries for Medicare Advantage beneficiaries in Georgia, starting Jan.1. Last year, the insurer rolled back th
- UAlbany Scientists Explore New Molecular Tool to Treat Retinal Degenerative Diseasehttps://modernod.com/news/ualbany-scientists-explore-new-molecular-tool-to-treat-retinal-degenerative-disease/2482011/University at Albany scientists at the College of Arts and Sciences’ RNA Institute, in collaboration with a research team from the University of Buffalo’s Jacobs School of Medicine and Biomedical Sciences, have received a 4-year, $1.8 million grant from the National Eye
- Ashley Magargee Named CEO of Genentechhttps://modernod.com/news/genentech-names-ashley-magargee-as-ceo/2482008/Ashley Magargee has been appointed Chief Executive Officer (CEO) of Genentech, effective January 1, 2024. In addition to her role as Head of US Commercial Portfolio, Ms. Magargee has been serving as ad interim CEO since the departure of Alexander Hardy on November 1, 2023. She will repo
- National Eye Institute Selects Richard Lee, MD, PhD, as Clinical Directorhttps://modernod.com/news/national-eye-institute-selects-richard-lee-md-phd-as-clinical-director/2481999/The National Eye Institute (NEI) has chosen Richard Lee, MD, PhD, as the institute’s clinical director, overseeing clinical research and serving as clinical policy advisor for NEI. Dr. Lee comes to NEI from Moorfields Eye Hospital, where he’s had several roles since 2011, th
- Genentech and Nvidia Enter Into Strategic AI Research Collaboration to Accelerate Drug Discovery and Developmenthttps://modernod.com/news/genentech-and-nvidia-enter-into-strategic-ai-research-collaboration-to-accelerate-drug-discovery-and-development/2481979/In a move aimed at speeding up drug discovery and development, Genentech announced a multi-year strategic research collaboration with Nvidia. Financial terms of the deal were not disclosed. The partnership will combine Genentech’s artificial intelligence
- World’s First Whole Eye & Partial Face Transplant Performed at NYU Langone Healthhttps://modernod.com/news/worlds-first-whole-eye-partial-face-transplant-performed-at-nyu-langone-health/2481958/A surgical team from NYU Langone Health performed the world’s first whole-eye and partial-face transplant for a 46-year-old military veteran from Arkansas who survived a work-related high-voltage electrical accident. The surgery included transplanting the entire left eye and a portion of th
- Nanoscope Therapeutics Wins 'Best of Show' Award at AAO Eyecelerator 2023https://modernod.com/news/nanoscope-therapeutics-wins-best-of-show-award-at-aao-eyecelerator-2023/2481955/Nanoscope Therapeutics was awarded the 'Best of Show in Retina' award at this year's American Academy of Ophthalmology (AAO) Eyecelerator conference held in San Francisco on Thursday, November 2, 2023. During the conference, Samuel Barone, MD, Nanoscope's chief